company background image

Uni-Bio Science Group SEHK:690 Stock Report

Last Price


Market Cap







13 Aug, 2022


Company Financials
690 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

690 Stock Overview

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China.

Uni-Bio Science Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Uni-Bio Science Group
Historical stock prices
Current Share PriceHK$0.08
52 Week HighHK$0.11
52 Week LowHK$0.054
1 Month Change-4.76%
3 Month Change11.11%
1 Year Change-20.00%
3 Year Change-54.29%
5 Year Change-59.60%
Change since IPO-83.53%

Recent News & Updates

Jan 05
Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

How far off is Uni-Bio Science Group Limited ( HKG:690 ) from its intrinsic value? Using the most recent financial...

Shareholder Returns

690HK BiotechsHK Market

Return vs Industry: 690 exceeded the Hong Kong Biotechs industry which returned -52.7% over the past year.

Return vs Market: 690 exceeded the Hong Kong Market which returned -21.6% over the past year.

Price Volatility

Is 690's price volatile compared to industry and market?
690 volatility
690 Average Weekly Movement10.1%
Biotechs Industry Average Movement7.8%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.6%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 690 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 690's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

2001326Frank Zhao

Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes.

Uni-Bio Science Group Fundamentals Summary

How do Uni-Bio Science Group's earnings and revenue compare to its market cap?
690 fundamental statistics
Market CapHK$509.18m
Earnings (TTM)-HK$19.59m
Revenue (TTM)HK$353.41m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
690 income statement (TTM)
Cost of RevenueHK$76.40m
Gross ProfitHK$277.01m
Other ExpensesHK$296.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)-0.0031
Gross Margin78.38%
Net Profit Margin-5.54%
Debt/Equity Ratio0%

How did 690 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is 690 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 690?

Other financial metrics that can be useful for relative valuation.

690 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA39x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 690's PS Ratio compare to its peers?

690 PS Ratio vs Peers
The above table shows the PS ratio for 690 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12x
8158 China Regenerative Medicine International
8247 Biosino Bio-Technology and Science Incorporation
1228 CANbridge Pharmaceuticals
1875 TOT BIOPHARM International
690 Uni-Bio Science Group

Price-To-Sales vs Peers: 690 is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (12x).

Price to Earnings Ratio vs Industry

How does 690's PE Ratio compare vs other companies in the HK Biotechs Industry?

Price-To-Sales vs Industry: 690 is good value based on its Price-To-Sales Ratio (1.4x) compared to the Hong Kong Biotechs industry average (26.7x)

Price to Sales Ratio vs Fair Ratio

What is 690's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

690 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 690's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 690 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 690's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 690's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Uni-Bio Science Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uni-Bio Science Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Uni-Bio Science Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Uni-Bio Science Group competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Uni-Bio Science Group performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 690 is currently unprofitable.

Growing Profit Margin: 690 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 690 is unprofitable, but has reduced losses over the past 5 years at a rate of 29.4% per year.

Accelerating Growth: Unable to compare 690's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.2%).

Return on Equity

High ROE: 690 has a negative Return on Equity (-11.24%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Uni-Bio Science Group's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 690's short term assets (HK$201.7M) exceed its short term liabilities (HK$92.3M).

Long Term Liabilities: 690's short term assets (HK$201.7M) exceed its long term liabilities (HK$985.0K).

Debt to Equity History and Analysis

Debt Level: 690 is debt free.

Reducing Debt: 690 has no debt compared to 5 years ago when its debt to equity ratio was 2.4%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 690 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 690 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 22.6% per year.

Discover healthy companies


What is Uni-Bio Science Group current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 690's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 690's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 690's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 690's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 690 has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Frank Zhao (57 yo)





Mr. Zhi GangZhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer at...

CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD199.65K) is about average for companies of similar size in the Hong Kong market ($USD246.27K).

Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 690's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Experienced Board: 690's board of directors are considered experienced (5.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Uni-Bio Science Group Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Uni-Bio Science Group Limited
  • Ticker: 690
  • Exchange: SEHK
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$509.181m
  • Shares outstanding: 6.36b
  • Website:

Number of Employees


  • Uni-Bio Science Group Limited
  • No. 20 Science Park East Avenue
  • Unit 502
  • Sha Tin
  • New Territories
  • Hong Kong


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/12 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.